Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) Director Jill M. Quigley sold 17,235 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $10.00, for a total transaction of $172,350.00. Following the completion of the sale, the director now owns 15,000 shares in the company, valued at approximately $150,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Terns Pharmaceuticals Stock Performance
TERN opened at $10.68 on Thursday. The company has a fifty day moving average of $7.97 and a two-hundred day moving average of $6.92. The stock has a market capitalization of $690.78 million, a price-to-earnings ratio of -8.48 and a beta of -0.37. Terns Pharmaceuticals, Inc. has a fifty-two week low of $3.26 and a fifty-two week high of $11.40.
Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.04. On average, equities research analysts forecast that Terns Pharmaceuticals, Inc. will post -1.31 earnings per share for the current year.
Analysts Set New Price Targets
Get Our Latest Report on Terns Pharmaceuticals
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in TERN. Decheng Capital LLC acquired a new stake in Terns Pharmaceuticals in the 4th quarter valued at $4,636,000. Great Point Partners LLC lifted its holdings in Terns Pharmaceuticals by 102.8% during the fourth quarter. Great Point Partners LLC now owns 1,309,975 shares of the company’s stock valued at $8,502,000 after purchasing an additional 664,076 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Terns Pharmaceuticals by 40.6% in the first quarter. Janus Henderson Group PLC now owns 2,003,263 shares of the company’s stock valued at $13,131,000 after purchasing an additional 578,500 shares during the period. Point72 Asset Management L.P. grew its position in shares of Terns Pharmaceuticals by 21.1% in the second quarter. Point72 Asset Management L.P. now owns 2,690,376 shares of the company’s stock valued at $18,321,000 after purchasing an additional 469,176 shares during the period. Finally, Affinity Asset Advisors LLC increased its stake in shares of Terns Pharmaceuticals by 581.8% during the first quarter. Affinity Asset Advisors LLC now owns 450,000 shares of the company’s stock worth $2,952,000 after purchasing an additional 384,000 shares in the last quarter. 98.26% of the stock is owned by institutional investors and hedge funds.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
Recommended Stories
- Five stocks we like better than Terns Pharmaceuticals
- What Does Downgrade Mean in Investing?
- 4 Stocks to Watch as Analysts Adjust Their Expectations
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Super Micro’s Delayed Filing: A Warning or an Opportunity?
- The 3 Best Fintech Stocks to Buy Now
- 3 Key Reasons Why Rocket Companies Stock Will Rally Soon
Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.